Repligen Corporation (RGEN) - Total Assets

Latest as of September 2025: $2.92 Billion USD

Based on the latest financial reports, Repligen Corporation (RGEN) holds total assets worth $2.92 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check RGEN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Repligen Corporation - Total Assets Trend (1985–2024)

This chart illustrates how Repligen Corporation's total assets have evolved over time, based on quarterly financial data. Explore RGEN long-term investment intensity to see how much of total assets are deployed in long-term investments.

Repligen Corporation - Asset Composition Analysis

Current Asset Composition (December 2024)

Repligen Corporation's total assets of $2.92 Billion consist of 37.7% current assets and 62.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 26.8%
Accounts Receivable $134.12 Million 4.7%
Inventory $142.96 Million 5.1%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $397.90 Million 14.1%
Goodwill $1.03 Billion 36.4%

Asset Composition Trend (1985–2024)

This chart illustrates how Repligen Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RGEN company net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Repligen Corporation's current assets represent 37.7% of total assets in 2024, a decrease from 68.9% in 1985.
  • Cash Position: Cash and equivalents constituted 26.8% of total assets in 2024, down from 61.2% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 1985.
  • Asset Diversification: The largest asset category is goodwill at 36.4% of total assets.

Repligen Corporation Competitors by Total Assets

Key competitors of Repligen Corporation based on total assets are shown below.

Company Country Total Assets
QITIAN Technology Group Co Ltd
SHE:300061
China CN¥1.17 Billion
Visco Vision Inc.
TW:6782
Taiwan NT$5.82 Billion
Daxor Corporation
NASDAQ:DXR
USA $35.90 Million
GETS Global Bhd
KLSE:5079
Malaysia RM400.10 Million
Osteopore Ltd
AU:OSX
Australia AU$2.77 Million
Safe Orthopaedics SA
PA:ALSAF
France €7.94 Million
Ansell Ltd
AU:ANN
Australia AU$3.33 Billion
Nanosonics Ltd
AU:NAN
Australia AU$279.25 Million

Repligen Corporation - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 8.36 10.44 2.83
Quick Ratio 7.14 8.76 2.53
Cash Ratio 0.00 0.00 0.00
Working Capital $965.35 Million $1.02 Billion $583.43 Million

Repligen Corporation - Advanced Valuation Insights

This section examines the relationship between Repligen Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.58
Latest Market Cap to Assets Ratio 2.62
Asset Growth Rate (YoY) 0.2%
Total Assets $2.83 Billion
Market Capitalization $7.41 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Repligen Corporation's assets at a significant premium (2.62x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Repligen Corporation's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Repligen Corporation (1985–2024)

The table below shows the annual total assets of Repligen Corporation from 1985 to 2024.

Year Total Assets Change
2024-12-31 $2.83 Billion +0.19%
2023-12-31 $2.82 Billion +11.57%
2022-12-31 $2.53 Billion +7.35%
2021-12-31 $2.36 Billion +23.94%
2020-12-31 $1.90 Billion +35.91%
2019-12-31 $1.40 Billion +904.03%
2018-12-31 $139.45 Million +15.81%
2017-12-31 $120.41 Million -58.32%
2016-12-31 $288.91 Million +97.56%
2015-12-31 $146.24 Million -323.52%
2014-12-31 $-65.43 Million -155.14%
2013-12-31 $118.64 Million +22.30%
2012-12-31 $97.01 Million +27.48%
2011-12-31 $76.10 Million +5.26%
2010-12-31 $72.29 Million +1.22%
2009-12-31 $71.42 Million -3.17%
2008-12-31 $73.75 Million +7.14%
2007-12-31 $68.84 Million +136.76%
2006-12-31 $29.08 Million +1.67%
2005-12-31 $28.60 Million +3.59%
2004-12-31 $27.61 Million -6.78%
2003-12-31 $29.61 Million -10.66%
2002-12-31 $33.15 Million +13.87%
2001-12-31 $29.11 Million -9.45%
2000-12-31 $32.15 Million -11.41%
1999-12-31 $36.29 Million +597.84%
1998-12-31 $5.20 Million -8.77%
1997-12-31 $5.70 Million -14.93%
1996-12-31 $6.70 Million +17.54%
1995-12-31 $5.70 Million -81.79%
1994-12-31 $31.30 Million -23.84%
1993-12-31 $41.10 Million -13.29%
1992-12-31 $47.40 Million -19.66%
1991-12-31 $59.00 Million +8.86%
1990-12-31 $54.20 Million +43.39%
1989-12-31 $37.80 Million +53.04%
1988-12-31 $24.70 Million -10.18%
1987-12-31 $27.50 Million +19.57%
1986-12-31 $23.00 Million +123.30%
1985-12-31 $10.30 Million --

About Repligen Corporation

NASDAQ:RGEN USA Medical Instruments & Supplies
Market Cap
$7.41 Billion
Market Cap Rank
#2809 Global
#987 in USA
Share Price
$131.69
Change (1 day)
+0.63%
52-Week Range
$102.87 - $172.26
All Time High
$324.21
About

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more